Surgery Partners, Inc. (SGRY) has a negative trailing P/E of -20.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 33.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -4.83%, forward earnings yield 3.00%. PEG 1.14.
Criteria proven by this page:
Overall SharesGrow Score: 42/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 80.5 | 0.20 | 78.65 | 0.66 | - |
| 2017 | -11.1 | 0.02 | 0.90 | 0.44 | 0.22% |
| 2018 | -2.3 | -0.01 | 1.16 | 0.27 | 1.66% |
| 2019 | -10.1 | 0.08 | 1.09 | 0.41 | - |
| 2020 | -12.2 | 0.03 | 2.57 | 0.76 | - |
| 2021 | -54.6 | 0.84 | 3.55 | 1.74 | 0.13% |
| 2022 | -46.9 | 0.99 | 1.28 | 1.01 | - |
| 2023 | -337.7 | 4.02 | 2.02 | 1.46 | - |
| 2024 | -15.9 | -0.01 | 1.49 | 0.86 | - |
| 2025 | -25.2 | 0.47 | 1.15 | 0.59 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $0.20 | $1.15B | $9.45M | 0.8% |
| 2017 | $-1.08 | $1.34B | $-52.99M | -4% |
| 2018 | $-4.28 | $1.77B | $-205.71M | -11.6% |
| 2019 | $0.95 | $1.83B | $46.1M | 2.5% |
| 2020 | $-3.19 | $1.86B | $-116.1M | -6.2% |
| 2021 | $-1.12 | $2.23B | $-70.9M | -3.2% |
| 2022 | $-0.59 | $2.54B | $-54.6M | -2.2% |
| 2023 | $-0.09 | $2.74B | $-11.9M | -0.4% |
| 2024 | $-1.33 | $3.11B | $-168.1M | -5.4% |
| 2025 | $-0.61 | $3.31B | $-77.9M | -2.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.39 | $-0.25 – $1.34 | $3.41B | $3.39B – $3.45B | 6 |
| 2027 | $0.48 | $0.22 – $0.79 | $3.6B | $3.52B – $3.74B | 6 |
| 2028 | $0.59 | $0.58 – $0.61 | $4.09B | $3.99B – $4.19B | 1 |
| 2029 | $0.85 | $0.83 – $0.88 | $4.52B | $4.45B – $4.66B | 1 |
